Discovers and develops novel ribonucleic acid (RNA) therapeutics. Focuses on treatments for hematology, cardiovascular, and rare/metabolic indications. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
An average decline of 54% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
Executives buying with their own money is usually read as confidence in the company’s future.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
The stock has been running stronger than the market lately.
Growth: Sales growth trails the sector average.
Business Quality: Profit power and business quality trail similar companies in the sector.
The stock trades 50% below its peak. The market has trimmed its expectations for the company.
Sales run at $559K a year. A small number, but proof the product has real buyers.
Over the last 12 months, company executives reported 15 buys and 0 sells. Management buying with its own money is usually read as a good sign.
A loss of $88.6M against $559K in annual sales. And on top of that, sales fell from the year before.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
On our five-subject report card, SLN sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: SLN is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (29/100) says the stock isn’t cheap.
Not covered, because the filings we hold do not carry it: the revenue breakdown.